Picture of Citius Pharmaceuticals logo

CTXR — Citius Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapValue Trap

Citius Pharmaceuticals Inc expected to post a loss of 7  cents a share - Earnings Preview

* Citius Pharmaceuticals Inc  CTXR.OQ   CTXR.O  is expected
to show no change in quarterly revenue when it reports 
results on May 11 (estimated). 
    * ​Refinitiv's mean analyst estimate for Citius
Pharmaceuticals
Inc is for a loss of 7 cents per share. For the same quarter
last year, the company reported a loss of 4 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Citius
Pharmaceuticals Inc is $6​, above​ its last closing price
of $1.04. ​​​

This summary was machine generated May 9 at 16:07 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Citius Pharmaceuticals

See all news